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The aim of the study was to see which method of taking vitamin D supplements (pill, liquid, skin 2 
application) resulted in the greatest increase in blood vitamin D levels. The oral pill had the best 3 
increase then skin application with a penetrator agent. 4 
Abstract 5 
Background: The use of vitamin D supplementation has increased due to greater recognition of 6 
widespread deficiency.  7 
Aims: There has been little research on the effectiveness of different delivery methods and therefore 8 
the aim of was to test the efficacy of different delivery methods on serum 25(OH)D. 9 
Methods: Using a randomised repeated measures double-blind placebo design (registered under 10 
ClinicalTrials.gov Identifier no. NCT03463642), changes in serum 25(OH)D over a 4-week period using 11 
a capillary spot method were monitored. 62 female participants blindly chose a number related to a 12 
supplementation delivery method: pill placebo, pill, oral liquid, oral liquid placebo, Skin oil 13 
application (SOA) placebo, SOA plus vitamin D3 suspension, or SOA plus vitamin D3 suspension with 14 
essential oil enhancer; active vitamin D supplements contained 100,000IU. Participants took their 15 
allocated supplements over a 24-hr period with serum 25(OH)D retested 4 weeks later. Liquid 16 
chromatography-tandem mass spectrometry method was applied to dried blood spot samples by an 17 
independent laboratory.  18 
Results: ANCOVA reported a significant difference between the groups (F1,6=146.68; p<0.001, eta2 = 19 
.51). Separate analysis within the delivery methods (pill, SOA, oral liquid) indicated significant 20 
differences between the active and placebo supplementation groups (p<0.01). Post hoc analysis of 21 
absolute changes indicated vit D pill and SOA + vit D + essential oil had significant increases (p<0.05) 22 
in serum 25(OH)D compared to all other interventions with no significant difference between them 23 
Conclusions: In human participants vitamin D oral pill has the greatest effect on serum 25(OH)D 24 
levels. Skin oil application delivery of vitamin D using a penetrator enhancer has also been shown to 25 
be an effective method of delivery. 26 
Keywords: Skin penetrator enhancer, pill, oral liquid, human, vitamin D,  27 
Introduction 28 
Vitamin D3 is mainly synthesized in the skin during exposure to ultraviolet light of the sun during the 29 
summer months 1,2, though food, specifically fatty fish, can also be a source 3. A recent study has 30 
suggested that exposure to sunlight might only have a limited effect 4; the Binkley et al. study 31 
indicated a variable response to sunlight exposure with some participants maintaining a low 32 
25(OH)D3 level despite abundant sun exposure. A recent review of the effect of sunscreen on serum 33 
25(OH)D concluded that sunscreen had little effect for healthy adults with recreational sunlight 34 
exposure5. The reviewed controlled studies, 3 showed no change and 4 showed a decrease in serum 35 
25(OH)D, though a series of methodological limitations including a lack of personal UVR exposure 36 
(n=4) and no baseline measure of serum 25(OH)D (n=3) highlight areas of concern. One short-term 37 
study (1-week high UVI exposure) noted significant increases in serum 25(OH)D in the sunscreen 38 
group (SPF 15) suggesting that only very low levels of UVB were required for the biosynthesis of 39 
vitamin D36. These studies only used sunscreens with a factor of 15-17, whilst a number of 40 
organisations, such as the American Cancer Society and the British Association of Dermatology, 41 
promote the use of higher protection (SPF 30-50). 42 
The current research indicates that to achieve optimal levels of 25(OH)D3, supplementation is 43 
required 7. Although there has been much research on supplementation dose levels there is still a lot 44 
of variation, this is possibly due to recommendations being targeted at specific clinical conditions, 45 
e.g. bone health. Ross et al 8 suggested 600 IU/day to maintain bone health, whilst others 9 have 46 
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suggested a higher daily dose (1500-2000 IU/day) is needed. Ekwaru et al 10 suggested that high 47 
doses had a diminishing effect with serum 25(OH)D3 increasing by 12nmol/L per 1000IU for 48 
supplementation between 0-1000 IU/day and only 1.1nmol/L for supplementation between 15,000-49 
20,000 IU/day and there was a need to account for body weight with obese patients requiring 2-3 50 
times more vit D and those overweight, 1.5 times. Other studies have utilised 1-2 high dose bolus 51 
supplementation to beneficial effect 11-14. 52 
There has been little research on different delivery methods for supplementation. Biancuzzo et al 15 53 
compared liquid and pill oral supplementation and noted no difference between the delivery 54 
methods. Leventis and Kiely 14 reported no difference between a single high bolus deliver by either 55 
intramuscular injection or tablet. A number of transdermal delivery methods have been examined 56 
with varying success16. Pre-treatment of ex-vivo skin with ethanol increased penetration but would 57 
eventually lead to toxicity17; Ramezanli et al18 used nanoparticles coated with hydrophillic and 58 
hydrophobic polymers to beneficial effect; whilst Devaux et al19 concluded that vitamin D enhanced 59 
creams applied to the skin only penetrates deep enough to treatment of skin disorders, such as 60 
psoriasis. Three studies have looked at the effect of penetration enhancers in vitamin D enhanced 61 
creams. D’ Angelo Costa et al20 used various penetration enhancers in either a gel or cream 62 
formulation on ex-vivo human skin; gel formulation with cereal alcohol and propylene glycol noted 63 
vitamin D3 penetration to stratum corneum (4 hours post application) and epidermis and dermis (24 64 
hours post application) but no active vitamin D3 was found in receptor fluid, therefore skin 65 
penetration was not fully achieved. Sadat-Ali et al 21 used aloe vera as a delivery system for dermal 66 
delivery of vitamin D and reported significant changes in serum 25(OH)D over a 3 month period. 67 
Essential oils have been shown to enhance different drugs ability to penetration the lower skin 68 
layers through either the disintegration of intercellular lipid structure between corneocytes and the 69 
conformational modification of proteins22. Bubshait et al23 used a proniosomal delivery system over 70 
a 4-month period with a similar beneficial effect on serum 25(OH)D. Therefore, topical delivery 71 
systems seem to be a safe and suitable delivery method of vitamin D. 72 
The aim of the present study was to examine the efficacy of different delivery methods on serum 73 
25(OH)D changes in healthy adult females. Various delivery methods of vitamin D supplementation 74 
are available to consumers but there have been no studies providing evidence of whether one 75 
delivery method is superior to others. We wanted to compare the delivery of 100,000IU vitamin D3 76 
by three methods. Two methods of oral supplementation (pill [prolonged release] and liquid 77 
[immediate release]), and delivery through the skin (with and without a penetrator enhancer). 78 
 79 
Materials and Methods 80 
Experimental design: The trial was a randomised double-blind placebo design and was registered 81 
with the US Clinical Trials (NCT03463642). An independent technician randomly assigned numbers 82 
(1-70) to the supplement samples: placebo pill, vitamin D pill, oral placebo liquid, oral vitamin D 83 
liquid, placebo skin oil application (SOA), SOA plus vitamin D3 suspension, or SOA plus vitamin D3 84 
suspension with essential oil enhancer. Volunteers then randomly selected a number between 1-70. 85 
The data collectors and the statistician were blind to the participant’s group (intervention or 86 
placebo) and only after the statistical analysis was completed were the group codes reviewed by the 87 
independent researcher. 88 
Participants: Advertisements were placed around campus and blast emails via the university 89 
intranet. Power analysis based upon effect size (0.8), alpha error probability (0.05),power 0.95, 7 90 
groups tested twice (repeated measures)24, estimated the required total sample size to be 40 91 
participants . To account for potential drop out 10 participants were recruited per group. Exclusion 92 
criteria included any participant that was taking vitamin supplementation, were non-Caucasian, had 93 
a skin condition that would prevent them from applying oil to their skin or were taking, had taken a 94 
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sunny holiday in the last 6-months, planned to take a sunny holiday during the study period, or had 95 
been taking in the past 6-months, oestrogen-based contraception 25. Seventy Caucasian volunteers 96 
were recruited from a female university population that included students and academics (latitude 97 
52.58o N) during the month of March. Sunlight hours during this month averaged 3.8 eight hours per 98 
day with a mean UV total index of 0.8626. Eight participants dropped out over the intervention 99 
period.  100 
Table 1: Participant descriptive data 101 











Pill Placebo 8 28 ±10.24 166.1 ±7.39 69.5 ±7.29 20.9 ±1.66 32.79 ±5.39  
Vit D 10 29 ±14.61 161.5 ±6.41 64.3 ±6.63 19.9 ±1.39 40.03 ±24.18 
Oral liquid Placebo 6 21 ±4.68 172.2 ±9.95 68.3 ±4.72 19.9 ±1.52 29.58 ±6.54 
Vit D 8 31 ±8.62 170.1 ±9.93 69.1 ±7.64 20.3 ±1.97 26.15 ±8.34 
Skin 
application 
Oil placebo 10 24 ±5.99 165.6 ±9.03 67.0 ±9.23 20.8 ±1.92 32.87 ±12.6 
Oil + Vit D 10 22 ±4.56 169.2 ±6.32 70.6 ±12.33 20.8 ±2.97 31.54 ±12.43  
Oil + Vit D + essential oil 10 27 ±11.71 166.3 ±5,32 68.8 ±9.28 20.7 ±2.61 33.87 ±20.39 




Figure 1: Participant flow chart 104 
Protocol: Participants read and signed an informed consent form prior to data collection.  Age 105 
(years), height (centimetres with a Seca height measure) and body mass (kg with digital Seca scale) 106 
5 
 
were collected on all participants prior to a blood sample. Using a capillary blood spot sample 107 
method, the tester used a single use lancet on the participant’s selected finger and the first show of 108 
blood was wiped away. Four blood spots were collected on the blood collection card (City Assays, 109 
Birmingham UK) making sure the spots were of sufficient size and had soaked through the paper. 110 
The card was then sealed before being sent to an independent laboratory for analysis (City Assays, 111 
Pathology Department Sandwell and West Birmingham Hospital NHS Trust, UK). Each participant 112 
was asked to select a number from a number grid 1-70. The relevant supplement sample was then 113 
issued to the participant with the instructions to complete the supplementation within 24 hours 114 
(table 2). The skin application group was asked to apply the oil twice in the 24-hour period on their 115 
limbs and torso until it was fully absorbed. The active pill and oral supplementations were all 116 
available commercially (Sunvit-D3 Ltd, UK), the active skin application used commercially available 117 
hypoallergenic mineral oil (Johnson & Johnson, Inc) combined with the aforementioned oral 118 
supplementation and the essential oil (Miaroma, France). The placebo supplements were either 119 
manufactured by a university pharmacy department (pills), commercially available syrup (PureGusto, 120 
UK) and hypoallergenic mineral oil (Johnson & Johnson, Inc). All participants confirmed completion 121 
of their supplementation via email to the independent researcher. Four weeks later participants 122 
were called in for their post-supplementation blood sample using the same methodology. Feedback 123 
was provided to each participant on their second test serum 25(OH)D3 levels and appropriate advice 124 
provided. The participants that had selected a placebo sample, were offered subsequent 125 
supplementation. 126 
Table 2: Intervention Groups 127 
 Active Placebo 
Pill 100 Vitamin D3 pills (1000IU, 
dicalcium phosphate, microcrystalline 
cellulose, silicium dioxide, magnesium 
stearate) 
 
100 pills (dicalcium phosphate, 
microcrystalline cellulose, silicium 
dioxide, magnesium stearate) 
Oral liquid 100 drops vitamin D3 suspension in 
orange syrup (1,000 IU per drop) 
 
100 drops of orange syrup 
Skin oil application 100,000 IU vitamin D3 suspension in 
mineral oil (paraffinum liquidum, 
isopropyl palmitate, parfum) (100ml 
total) 
 
100ml of mineral oil (paraffinum 
liquidum, isopropyl palmitate, 
parfum) coloured with food colourant 
to match active oil sample 
 100,000 IU vitamin D3 suspension in 
mineral oil (paraffinum liquidum, 
isopropyl palmitate, parfum) with 




Blood analysis: 129 
A liquid chromatography-tandem mass spectrometry (LC-MS/MS) method was applied to dried 130 
blood spot samples, utilising blood spot calibrators27. The method is standardised against 131 
conventional 25-hydroxyvitamin D3 and D2 LC-MS/MS service for serum (r2=0.98; intra assay 132 
variation <10%; inter assay variation <11%). Blood spot results show good comparability to 133 
serum/plasma results with a 3.3% difference (95% CI: -6.3-12.1%; p=0.48)28. The City Assays 134 
laboratory participates in the DEQAS external quality assurance scheme. 135 
 136 
Data analysis: 137 
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Group data were tested for homogeneity/sphericity prior to further analysis using Levene’s test of 138 
equality of variance (SPSS v20). Analysis of covariance (ANCOVA) was conducted to detect changes in 139 
serum 25(OH)D; the dependent variable was post vitamin D3; fixed factors were the different groups 140 
(pill placebo, pill, oral liquid, oral liquid placebo, skin oil application [SOA] placebo, SOA plus vitamin 141 
D3 suspension, or SOA plus vitamin D3 suspension with essential oil enhancer), and pre vitamin D3 142 
was the covariate. Bonferroni post hoc analyses were used where applicable. Analysis of variance 143 
within the delivery methods (pill, skin oil application, oral liquid) was carried on the absolute change 144 
in serum 25(OH)D with Bonferroni post hoc analyses. Significance for all analyses was set at p≤0.05. 145 
  146 
Results  147 
Pre-intervention there were no statistical differences between the groups for anthropometric 148 
measurements or baseline serum 25(OH)D (p>0.05). Post-intervention ANCOVA reported a 149 
significant difference in serum 25(OH)D between the groups (F1,6=146.68; p<0.001, eta2 = .51); post 150 
hoc comparisons revealed that SOA placebo, SOA +vit D, oral liquid placebo and pill placebo groups 151 
did not significantly increase (p>0.05). The vit D pill group had significantly higher serum 25(OH)D 152 
than the following groups: SOA placebo (p < .01), SOA +vit D (p < .05), oral liquid placebo (p < .01) 153 
and pill placebo (p < .01). For the active supplementation groups, no significant difference was noted 154 
between them with the exception of vit D pill group and SOA +vit D (p<0.01) (Table 3). 155 
Table 3: Pre and post intervention serum 25(OH)D3 for the different delivery methods 156 
[mean, standard deviation (95%CI)] 157 
Delivery method Pre Post Change 
  nmol.L-1  
Pill Placebo 32.79 ±5.39 (28.28, 37.29) 32.89 ±5.23 (28.52, 
37.27) 
0.11 ±1.31 (-6.87, 7.09) 
 
Vit D 40.03 ±24.018 (21.45, 
58.62) 
74.39 ±34.26 (42.70, 
106.07)Ŧ 
26.03 ±19.68 (18.57, 
33.49)‡ 
Oral liquid Placebo 29.58 ±6.54 (22.71, 36.44) 31.61 ±5.75 (25.57, 
37.62) 
2.04 ±2.90 (-6.02, 
10.10) 
Vit D 26.15 ±8.34 (19.18, 33.12) 34.40 ± 6.47  (28.99, 
39.81)Ŧ 




Oil placebo 32.87 ±12.6 (20.84, 44.90) 30.77 ±29.25 
(22.45,39.09) 
7.81 ±10.59 (0.83, 
14.79) 
Oil + Vit D 31.54 ±12.43 (21.15, 
41.93) 
33.73 ±15.38 (20.86, 
46.59) 
2.19 ±7.05 (-4.79, 9.17) 
 
Oil + Vit D + 
essential oil 
33.87 ±20.39 (18.19, 
49.54) 
48.13 ±28.71 (18.00, 
78.26)Ŧ 
14.92 ±10.80 (6.86, 
22.98)‡ 
Ŧ Significant changes over time (p<0.05); ‡significantly greater change 158 
Analysis of the actual change in serum 25(OH)D between the pre and post- tests indicated significant 159 
differences (F6,49=5.016, p<0.001; eta2 = .55) between the supplementation methods. Within each 160 
delivery method (pill, skin oil application, oral liquid) there were significant differences between the 161 
active and placebo supplementation groups (p<0.01). Post hoc analysis indicated that vit D pill and 162 
SOA + vit D + essential oil had significantly greater increases in serum 25(OH)D compared to all other 163 
interventions (p<0.05). There was no significant difference in the amount of serum 25(OH)D change 164 
between them. The skin oil application groups reported a significant difference between the SOA + 165 
vit D + essential oil and both the SOA + vit D and SOA placebo groups (Fig 2), but not between the 166 




Figure 2: Serum 25(OH)D changes over time for the different delivery methods 169 
 170 
Discussion 171 
Vitamin D insufficiency, within the general population, has been highlighted in both the academic 172 
and popular press over the last decade 2,7,29,30 with the advice to take supplementation 31-34 especially 173 
during the winter months.. Previous studies have examined the effects of different supplementation 174 
doses on serum 25(OH)D 8,9,35. Consumers have an array of different supplementation methods 175 
available (pill, liquid, skin oil application, nasal spray, injection etc) without evidence of their efficacy. 176 
Biancuzzo et al 15 compared liquid and oral vitamin D supplementation and the present study added 177 
skin oil application to examine the efficacy of different delivery methods. With the exception of 178 
vitamin D skin oil application, all the vitamin D active supplementation methods significantly 179 
increased serum 25(OH)D compared with their equivalent placebo. The greatest change in serum 180 
25(OH)D for an equal supplementation dose (100,000IU) was noted for pill supplementation (26.03 181 
±19.68 nmol.L-1) followed by skin oil application with essential oil (14.92 ±10.80 nmol.L-1) and finally 182 
oral liquid (8.25 ±4.29 nmol.L-1). Skin oil application without the addition of an essential oil reported 183 
a similar change as the placebo groups but less than the other active interventions. 184 
Biancuzzo et al 15 supplemented participants over a 11-week period with 1000IU/day and reported 185 
no significant difference between the two delivery methods (oral liquid and pill) though the liquid 186 
supplementation increase was approximately 70% whilst the pill supplementation was 42%. In our 187 
study participants took the equivalent of 100,000IU over a 24-hr period. The reduced efficacy of 188 
bolus oral liquid versus slower release pill may be due to rate limited hepatic hydroxylation of vit D 189 
to 25(OH)D following rapid intestinal absorption. The benefits of an essential oil as a dermalogical 190 
penetration enhancer is highlighted with the significantly greater absorption rates between the 191 
different skin application groups. Human skin has a multifunctional role but one of its primary 192 
functions is to act as a barrier against xenobiotic materials such as drugs 36. The penetration 193 
enhancer interacts with the skin’s stratum corneum, disrupting its lipid bilayers by modifying 194 
permeant diffusivity 37, thereby reducing the barrier properties. This may be due to the competitive 195 
hydrogen bonding of oxygen containing monoterpenes with ceramide head groups, thereby 196 
breaking the interlamellar hydrogen bonding network of lipid bilayer of stratum corneum and new 197 
polar pathways or channels are formed. This study highlights the efficacy of essential oils as a 198 
penetration enhancer in the delivery of vitamin D across the skin barrier. D’Angelo Costa et al20 used 199 
the same amount of vitamin D3 (100,000IU) on ex-vivo skin application but used different 200 
penetration enhancers (cereal alcohol, soybean lecithin, isopropyl palmitate, propylene glycerol and 201 
ethoxydiglycol) and although they noted vitamin D3 did reach the epidermis and dermis within 24 202 
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hours, it was not detectable in the receptor fluid.  A direct comparison to Sadat-Ali et al 21 study is 203 
not possible as in that study the total amount of vitamin D delivered was not reported beyond the 204 
concentration of the gel (5000IU/gram). The total usage of the gel, area of the body applied to and 205 
frequency was not reported. The current study only recruited female participants within a 206 
premenopausal age range to increase the compliance with skin application and reduce possible 207 
confounding; further studies are required to examine whether there are sex or age effects. 208 
A limitation of the current study could be participant compliance the administration of the 209 
interventions. Although we asked for confirmation that the supplement had been taken/used within 210 
the 24-hour time period direct observation of the administration might have strengthen the 211 
methodology particularly in the oral pill and skin application conditions. The size of the bolus 212 
(100,000IU) particularly the active oral liquid supplementation could have saturated the absorption 213 
capabilities of the gut if taken all at once and a more measured ingestion of three intakes over the 214 
24-hour period might have been more efficacious. The drop-out of participants within the study was 215 
an issue, all participants were from an academic environment and the issue was scheduling post-216 
intervention tests before a vacation and placement periods, this asymmetrically effected the oral 217 
liquid groups more than the other groups. 218 
The present study has highlighted the effectiveness of different vitamin D supplementation delivery 219 
methods. It has demonstrated that dermal delivery in the presence of a penetration enhancer is as 220 
beneficial as oral supplementation. In patients that already take a number of oral medications there 221 
is increased risk of non-compliance 38 and therefore an alternative to oral supplementation is 222 
beneficial. The use of high dose oral pill bolus, to reduce the potential of non-compliance has been 223 
reported previously 12,34 and the present study has underlined this outcome for oral pill and liquid 224 
delivery and dermal delivery.  225 
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